Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer
NCT04017650Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, KL-140, nivolumab in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2019; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04017650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017650.